Fundacio Institut de Recerca Contra la Leucemia Josep Carreras

Fundacio Institut de Recerca Contra la Leucemia Josep Carreras is a research organisation in Badalona, Spain that has taken part in 43 EU-funded projects since 2013, receiving €21.5M in EU funding and leading 23 as coordinator.

EU funding received€21.5M
EU projects43
As coordinator23
Running now16
First EU project2013
Latest project2027
CountrySpain
EU registration (PIC)951078308
On this page · 5 sections→

Where the EU money came from

Funding by EU programme. Amounts are Fundacio Institut de Recerca Contra la Leucemia Josep Carreras's own share of each project, not the project's full budget.

  • Horizon Europe€15.2M · 24 projects
  • Horizon 2020€6.1M · 17 projects
  • FP7 (2007 to 2013)€193k · 2 projects

Projects

43 EU-funded projects, newest first. Fundacio Institut de Recerca Contra la Leucemia Josep Carreras led 23 of them as coordinator. Each links to the official record.

  • ProofReadingAssociated partner

    European doctoral network for proofreading the proteome

    Horizon Europe · 2027–2030 · Project on CORDIS ↗

  • NAVIGATEAssociated partner

    Next-generation AI and Computational Biology for Translational Excellence

    Horizon Europe · 2026–2032 · Project on CORDIS ↗

  • ACHILLESCoordinator

    Advancing in the CHallenge of Improving Lymphoma and LEukemia Survival

    Horizon Europe · 2025–2029 · Project on CORDIS ↗

    €564ktheir share
  • MakingBloodPartner

    Engineering an integrated platform for generation of human blood stem cells from pluripotent sources

    Horizon Europe · 2025–2031 · Project on CORDIS ↗

    €738ktheir share
  • BEMOSAICCoordinator

    Decoding endothelial cell BEhavioral MOSAICism within single vessels

    Horizon Europe · 2025–2031 · Project on CORDIS ↗

    €3.5Mtheir share
  • NUCLEARCoordinator

    METABOLIC REGULATION OF GENOME FUNCTION AND CELL IDENTITY

    Horizon Europe · 2025–2029 · Project on CORDIS ↗

    €504ktheir share
  • AdaptmetPartner

    Deconstructing adaptive evolution of metastasis

    Horizon Europe · 2025–2029 · Project on CORDIS ↗

    €252ktheir share
  • CARLYCoordinator

    Development and characterization of a novel CAR T-cell therapy for NHL

    Horizon Europe · 2025–2027 · Project on CORDIS ↗

    €226ktheir share
  • HubMOLPartner

    Hub Molecules of Metabolism and Signalling – Key regulators of Life

    Horizon Europe · 2025–2028 · Project on CORDIS ↗

    €252ktheir share
  • IRB-TARGETAssociated partner

    IRB Barcelona International PhD programme: on TARGET for high-impact biomedicine

    Horizon Europe · 2024–2029 · Project on CORDIS ↗

  • CarrerasPathfindersCoordinator

    Enabling the next generation in search of blood cancer cures

    Horizon Europe · 2024–2029 · Project on CORDIS ↗

    €1.9Mtheir share
  • ChroMetCoordinator

    Elucidating the role of macroH2A1.2 histone variant as a metabolic sensor in the epigenetic regulation of leukaemia cell fate.

    Horizon Europe · 2024–2026 · Project on CORDIS ↗

    €165ktheir share
  • FUN-HSCCoordinator

    TACKLING FUNCTIONAL MATURATION FOR TRANSPLANTABLE HEMATOPOIETIC STEM CELL GENERATION

    Horizon Europe · 2024–2028 · Project on CORDIS ↗

    €2.1Mtheir share
  • IMMERGECoordinator

    Storming Immune Monogenic Conditions through Multiomic and Gene Editing Approaches

    Horizon Europe · 2024–2027 · Project on CORDIS ↗

    €756ktheir share
  • THRIVEPartner

    TUMOUR-HOST INTERACTIONS IN LIVER CANCER OF CHILDHOOD AND ADULTS

    Horizon Europe · 2023–2028 · Project on CORDIS ↗

    €690ktheir share
  • SIRT7-LCCoordinator

    Role of the SIRT7-NPM-c-Myc pathway in lung cancer

    Horizon Europe · 2023–2025 · Project on CORDIS ↗

    €165ktheir share
  • ALERTCoordinator

    Contribution of Lipid Droplets to the pathogenesis and chemoresistance of Acute Myeloid Leukemia

    Horizon Europe · 2023–2026 · Project on CORDIS ↗

    €226ktheir share
  • BiTE-CARCoordinator

    CD22/CD19 dual redirection Dual targeting of CD22 and CD19 with BiTE-secreting and CAR-expressing bispecific T-cells for adoptive Cellular ImmunoTherapy in advanced B-cell Acute Lymphoblastic Leukemia

    Horizon Europe · 2023–2025 · Project on CORDIS ↗

    €150ktheir share
  • CARxALLAssociated partner

    Next generation, off-the-shelf, non fratricide-directed, CAR immunotherapy for relapse/refractory T-cell acute lymphoblastic leukemia

    Horizon Europe · 2023–2026 · Project on CORDIS ↗

  • StemLincCoordinator

    Identification and characterization of long non-coding RNAs as drivers of stemness in hematopoietic stem cells and leukemia.

    Horizon Europe · 2023–2024 · Project on CORDIS ↗

    €165ktheir share
  • CarrerasLeadersCoordinator

    Carreras Postdoc Program Empowering Future Leaders to Fight Blood Cancers

    Horizon Europe · 2023–2028 · Project on CORDIS ↗

    €2.3Mtheir share
  • Maxima ButterflyAssociated partner

    From Caterpillar to BUTTERFLY: supporting transformation of DCs in a paediatric oncology network

    Horizon Europe · 2023–2027 · Project on CORDIS ↗

  • SECUREDPartner

    Scaling Up secure Processing, Anonymization and generation of Health Data for EU cross border collaborative research and Innovation

    Horizon Europe · 2023–2025 · Project on CORDIS ↗

    €230ktheir share
  • PROS-VARIANTCoordinator

    PIK3CA-Related Overgrowth Spectrum: molecular mechanisms and preclinical modelling of PIK3CA VARIANTs

    Horizon 2020 · 2022–2024 · Project on CORDIS ↗

    €161ktheir share
  • CANCERNAPartner

    RNA PROCESSING FOR ANTI-CANCER IMMUNOTHERAPY

    Horizon Europe · 2022–2025 · Project on CORDIS ↗

    €351ktheir share
  • SENAGECoordinator

    Senescence as a key factor in leukemogenesis and bone marrow homeostasis in aging

    Horizon 2020 · 2021–2023 · Project on CORDIS ↗

    €173ktheir share
  • PIPgenCoordinator

    PI3K/PTEN-related monogenic disease to understand cancer

    Horizon 2020 · 2021–2025 · Project on CORDIS ↗

    €502ktheir share
  • EvometPartner

    Deconstructing the evolution of metastasis

    Horizon 2020 · 2021–2025 · Project on CORDIS ↗

    €502ktheir share
  • INTERCEPT-MDSCoordinator

    Exploring cell-to-cell heterogeneity and exploiting epigenetic regulation for the interception of myeloid disease cells.

    Horizon 2020 · 2021–2024 · Project on CORDIS ↗

    €753ktheir share
  • IT4-TALLCoordinator

    Clinical translation of a novel CD1a-directed CAR for relapse/refractory cortical T-cell Acute Lymphoblastic Leukemia: feasibility, efficacy and safety

    Horizon 2020 · 2021–2022 · Project on CORDIS ↗

    €150ktheir share
  • SirT-IMLEUCoordinator

    Mechanisms of Sirtuin-dependent regulation of immunity and leukemogenesis

    Horizon 2020 · 2020–2022 · Project on CORDIS ↗

    €173ktheir share
  • HARMONY PLUSPartner

    HEALTHCARE ALLIANCE FOR RESOURCEFUL MEDICINES OFFENSIVE AGAINST NEOPLASMS IN HEMATOLOGY – PLUS

    Horizon 2020 · 2020–2024 · Project on CORDIS ↗

    €90ktheir share
  • cONCReTEPartner

    DevelOpmeNt of Cancer RNA TherapEutics

    Horizon 2020 · 2020–2025 · Project on CORDIS ↗

    €110ktheir share
  • HifLICsCoordinator

    Acute Myeloid Leukemia Leukemic Initiating Cells: Contribution of hypoxia/HIF pathway to chemoresistance and relapse

    Horizon 2020 · 2019–2020 · Project on CORDIS ↗

    €158ktheir share
  • IT4B-ALLCoordinator

    Therapeutic immunotherapy targeting NG2 and CD22 antigens for MLL-rearranged and MLL-germline B-cell Acute Lymphoblastic Leukemia

    Horizon 2020 · 2019–2020 · Project on CORDIS ↗

    €150ktheir share
  • CLOSERPartner

    Childhood Leukemia: Overcoming distance between South America and Europe Regions

    Horizon 2020 · 2019–2024 · Project on CORDIS ↗

    €151ktheir share
  • InTheMLLrBALLCoordinator

    Innovative Therapeutic Strategies for Mixed Lineage Leukemia-rearranged B-cell Acute Lymphoblastic Leukemia

    Horizon 2020 · 2018–2020 · Project on CORDIS ↗

    €158ktheir share
  • HARMONYPartner

    Healthcare Alliance for Resourceful Medicines Offensive against Neoplasms in HematologY - Sofia ref.: 116026

    Horizon 2020 · 2017–2023 · Project on CORDIS ↗

    €153ktheir share
  • ChroMePartner

    Chromatin and Metabolism Chromatin-metabolism interactions as targets for healthy living

    Horizon 2020 · 2016–2020 · Project on CORDIS ↗

    €496ktheir share
  • INFANTLEUKEMIACoordinator

    GENOMIC, CELLULAR AND DEVELOPMENTAL RECONSTRUCTION OF INFANT MLL-AF4+ ACUTE LYMPHOBLASTIC LEUKEMIA

    Horizon 2020 · 2016–2021 · Project on CORDIS ↗

    €2.0Mtheir share
Show 3 more projects
  • RELEVANCEPartner

    Regulation of red cell life-span, erythropoiesis, survival, senescence and clearance

    Horizon 2020 · 2015–2019 · Project on CORDIS ↗

    €238ktheir share
  • MODELING MLL-AF4 ALLPartner

    Cell of origin/Leukemia Initiating Cell in infant Pro-B MLL-AF4+ ALL

    FP7 (2007 to 2013) · 2014–2018 · Project on CORDIS ↗

    €63ktheir share
  • COMMITMENTPartner

    Combined Molecular Microscopy for Therapy and Personalized Medication in Rare Anaemias Treatments

    FP7 (2007 to 2013) · 2013–2018 · Project on CORDIS ↗

    €130ktheir share

Works most with

Organisations that shared the most EU projects with this one. A good starting list for consortium partners.

Fields it works in

Research fields recorded on its Horizon projects.

  • DNA
  • RNA
  • artificial intelligence
  • big data
  • biochemistry
  • bioreactors
  • cell biology
  • cell signaling
  • cells technologies
  • civil society
  • composites
  • databases
  • diabetes
  • drug discovery

Is this your organisation?

Claim it with an EUACC listing (€39 once, reviewed by our editors): add what you build, your team and what you are looking for. We pre-fill it from your EU records. Listed companies reach investors through our newsletter and get matched to new EU calls first.

Claim this profile →

Source: CORDIS (Horizon Europe, Horizon 2020, FP7) and the EU Funding & Tenders Portal (other EU programmes), matched by the EU registration number (PIC). Past participation does not mean the organisation is open to new partnerships. Official website ↗

Europe’s tech funding.
One place.

The weekly briefing

Funding calls, VC news and key deadlines — a weekly briefing for European founders.

Free · unsubscribe anytime